Ikarian Capital, LLC Arvinas, Inc. Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $4.19 Million - $5.8 Million	100,000 New	100,000 $4.45 Million
Q4 2020 Feb 12, 2021	BUY	$20.19 - $84.93 $1.47 Million - $6.2 Million	73,000 Added 45.71%	232,700 $19.8 Million
Q3 2020 Nov 16, 2020	BUY	$22.99 - $36.34 $1.23 Million - $1.95 Million	53,600 Added 50.52%	159,700 $3.77 Million
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $1.49 Million - $2.84 Million	50,000 Added 89.13%	106,100 $3.56 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $1.75 Million - $2.89 Million	53,000 Added 1709.68%	56,100 $2.26 Million
Q4 2019 Jan 31, 2020	BUY	$15.39 - $44.38 $47,709 - $137,578	3,100 New	3,100 $127,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.38B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.